FindTrial
Sign In

A study on the use of smart tissue analysis to improve the speed and accuracy of cancer diagnosis and outcome prediction in patients

HISTOQUANTA - An intuitive immunohistochemistry profiling application for simplifying cancer diagnosis and prognosis. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/101917
Enrollment
100
Registered
2026-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C501- Malignant neoplasm of central portion of breast

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Comprehensive Onco IHC Multiplex Panel: Comprehensive immunohistochemistry profiling using predefined multi marker to guide diagnosis and

Sponsors

Saveetha medical college hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with confirmed cancer diagnosis where immunohistochemistry profiling is performed to assess diagnostic markers or prognostic outcomes.

Exclusion criteria

Exclusion criteria: Cases lacking histopathological confirmation, incomplete IHC data, or non-cancer conditions where IHC is not applied for diagnosis/prognosis.

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy and prognostic value including disease free survival and overall survival.Timepoint: day 1 after diagnosing cancer—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactJayaganesh P

Saveetha medical college hospital.

sinegasivasamy95@gmail.com8637671318

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026